- Home
- MASS vs PLRX Comparison
MASS vs PLRX Comparison
Compare MASS & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MASS
- PLRX
- Stock Information
- Founded
- MASS 2012
- PLRX 2015
- Country
- MASS United States
- PLRX United States
- Employees
- MASS N/A
- PLRX N/A
- Industry
- MASS Medical/Dental Instruments
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- MASS Health Care
- PLRX Health Care
- Exchange
- MASS Nasdaq
- PLRX Nasdaq
- Market Cap
- MASS 84.3M
- PLRX 77.3M
- IPO Year
- MASS 2020
- PLRX 2020
- Fundamental
- Price
- MASS $6.90
- PLRX $1.40
- Analyst Decision
- MASS Buy
- PLRX Hold
- Analyst Count
- MASS 3
- PLRX 10
- Target Price
- MASS $5.33
- PLRX $9.79
- AVG Volume (30 Days)
- MASS 699.4K
- PLRX 1.6M
- Earning Date
- MASS 08-05-2025
- PLRX 08-06-2025
- Dividend Yield
- MASS N/A
- PLRX N/A
- EPS Growth
- MASS N/A
- PLRX N/A
- EPS
- MASS N/A
- PLRX N/A
- Revenue
- MASS $63,986,000.00
- PLRX N/A
- Revenue This Year
- MASS N/A
- PLRX N/A
- Revenue Next Year
- MASS $22.44
- PLRX N/A
- P/E Ratio
- MASS N/A
- PLRX N/A
- Revenue Growth
- MASS 32.85
- PLRX N/A
- 52 Week Low
- MASS $1.81
- PLRX $1.10
- 52 Week High
- MASS $8.06
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- MASS 53.47
- PLRX 54.68
- Support Level
- MASS $6.33
- PLRX $1.13
- Resistance Level
- MASS $7.27
- PLRX $1.27
- Average True Range (ATR)
- MASS 0.44
- PLRX 0.11
- MACD
- MASS -0.05
- PLRX 0.02
- Stochastic Oscillator
- MASS 45.60
- PLRX 90.00
About MASS 908 Devices Inc.
908 Devices Inc manufactures medical devices. It has developed a suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company geographically derives maximum revenue from United States, and also has its presence in Europe, Middle East and Africa, Americas and Other and Asia Pacific.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.